Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Diabetic Nephropathies

• Treatment of Patients With Diabetic Kidney Disease
• Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy
• Clinical Study on the Treatment of Diabetic Kidney Disease With Shenxiao Yuning Decoction With Syndrome of Qi and Yin Deficiency and Blood Stasis
• Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia
• The Impact of Sitagliptin as an Add on Therapy With Closed Loop Control in Adolescents With Diabetic Nephropathy
• Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation
• Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy
• Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - A Pilot Study
• Randomized Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
• The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy
• NAD Augmentation in Diabetes Kidney Disease
• Azilsartan in Patients With Diabetic Kidney Disease and Hypertension
• Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria
• A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
• A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
• Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease
• Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease
• Phase 2, Efficacy, Safety, and Pharmacokinetics Study of Two INV-202 Doses in Patients With Diabetic Kidney Disease
• Renal Mechanism of SGLT2 Inhibition
• Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC73077 in Healthy Subjects
• Investigational and Comparative Study in the Management of Diabetic Nephropathy
• Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)
• Huangqi Guizhi Wuwu Decoction in CKD Stage 2-4 Diabetic Nephropathy
• PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
• Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease
• Targeting Leukotrienes in Kidney Disease
• Double-blind Randomized Controlled Trial Investigating the Effects of Calcitriol on Biomarkers in Diabetic Kidney Disease Patients
• Basal Plus GLP1-ra on Glycemic Variability in CKD
• The Effects of TMZ on Diabetic Nephropathy
• MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
• Study on the Efficacy and Safety of a Novel Tripterygium Wilfordii Preparation in Reducing Proteinuria in Patients With Diabetic Nephropathy
• A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes
• A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, We
• SER150 vs Placebo in Diabetic Kidney Disease
• First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes
• Stem Cell Therapy for Chronic Kidney Disease
• Possible Role of Roflumilast in Diabetic Nephropathy
• A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease
• Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
• Gemigliptin and Biomarkers of Kidney Injury and Vascular Calcification
• A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels.
• Randomized Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease
• Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe
• Atrasentan in Patients With Proteinuric Glomerular Diseases
• Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy
• Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy
• Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy
• Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
• A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
• Niclosamide Role in Diabetic Nephropathy
• Renohemodynamic Effects of Combined empagliflOzin and LosARtan
• Role of Fexofenadine in Diabetic Kidney Disease
• A Phase 2b Diabetic Kidney Disease Study
• Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination
• Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes
• Umbilical Cord Mesenchymal Stem Cells Therapy for Diabetic Nephropathy
• Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria
• Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.
• Study Evaluating the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease
• Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)
• Uric Acid Lowering Trial in Youth Onset T2D
• Evaluation of Coffee Therapy for Improvement of Renal Oxygenation
• Effects of Fenofibrate Therapy in Diabetic Nephropathy
• Oral LAT8881 in Neuropathic Pain
• Magnesium Supplementation in Diabetic Nephropathy
• Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy
• the Integrated Traditional Chinese and Western Medicine Treat Early Stage DKD
• the Integrated Traditional Chinese and Western Medicine Treat Middle Stage DKD
• Pentoxifylline Effect in Patients With Diabetic Nephropathy.(PENFOSIDINE STUDY)
• Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan
• Pentoxifylline in Diabetic Kidney Disease
• Green Tea Extract on Soluble RAGE in Patients With Diabetic Nephropathy
• Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes
• Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function
• Vitamin B Complex and Diabetic Nephropathy in Type 1 Diabetes
• Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients
• A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study
• Efficacy, Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease
• Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)
• Safety and Efficacy of Two Year Spnol and Maximal R Blockad Therapy
• Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria
• Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
• A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease
• Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease
• A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
• An Intervention to Examine the Effect of Vitamin D on Urine Protein Levels in Type 2 Diabetes
• Empaglifozin in Early Diabetic Kidney Disease
• This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated
• This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)
• Efficacy and Safety of Jinshuibao Capsule on Diabetic Kidney Disease
• Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan
• IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease
• EMPRA (EMPagliflozin and RAs in Kidney Disease)
• Clinical Trial of HuangKui Capsule to Treat Diabetic Kidney Disease
• The Multi-Center Clinical Study of Tang Shen Prescription on Type 2 Diabetic Kidney Disease in Early Stage
• Add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on NT-PRO BNP in Type 2 Diabetics With Nephropathy
• Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes
• Microalbuminuria and Allopurinol in Type 1 Diabetes
• CPAP Effect on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea
• Telmisartan Promotes the Differentiation of Monocytes Into Macrophages M2 in Diabetic Nephropathy?
• Resveratrol's Effects in Diabetic Nephropathy
• Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy
• Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy
• Renoprotective Effects of Dapagliflozin in Type 2 Diabetes
• An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy
• Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy
• A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy
• Antiproteinuric Effects of Liraglutide Treatment
• Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
• Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
• Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy
• Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function
• Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
• Semi-individualised Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy
• Colchicine for Diabetic Nephropathy Trial
• Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria
• Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)
• A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria
• Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout
• Effect of LIXIsenatide on the Renal System
• Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients
• Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy
• Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
• Pyridorin in Diabetic Nephropathy
• The Differential Effects of Diabetes Therapy on Inflammation
• Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
• Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria
• Low-dose Colchicine in Patients With Type 2 Diabetes Mellitus and Microalbuminuria
• A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
• Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
• The Phase I Clinical Study to Evaluate the Pharmacokinetics of Dw1029M in Healthy Male Volunteer
• Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)
• To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy
• Effect of Green Tea (Epigallocatechin Gallate) on Albuminuria in Patients With Diabetic Nephropathy.
• Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease
• Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy
• Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
• Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)
• Study Of Diabetic Nephropathy With Atrasentan
• The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease
• Beraprost Sodium and Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy
• Minocycline and Proteinuria in Diabetic Nephropathy
• Study of LY3016859 in Participants With Diabetic Nephropathy
• A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR
• A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria
• Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease
• Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy
• Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
• A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
• FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients
• Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease
• A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
• Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy
• Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure
• Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
• Renal Denervation in Diabetic Nephropathy
• A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
• Mycophenolate Mofetil, Carnitine and PDE5 Inhibitor, Three Potential Treatments for Resistant Proteinuria Slowing Diabetic Nephropathy Deterioration
• The Effects of Sevelamer Carbonate on Diabetic Nephropathy
• A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
• A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
• Vitamin D Supplementation in Diabetic Nephropathy
• A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
• A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria
• Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan
• A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy
• Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)
• Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled D
• Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy
• Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499
• The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.
• Effect of Sulodexide on Albuminuria in Chinese Type 2 Diabetic Patients
• N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
• A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy
• Impact of Vitamin D on Diabetic Kidney Disease in African Americans
• A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
• A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy
• Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
• A Study in Participants With Diabetic Kidney Disease
• The Effects of Bindarit in Diabetic Nephropathy
• Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease
• Effects of PH3 in Diabetic Nephropathy
• Pancreas Allotransplantation for Diabetic Nephropathy and Mild Chronic REnal fAilure Stage Study
• Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)
• Effect of Turmeric on Diabetic Nephropathy
• Colchicine for Diabetic Nephropathy
• Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy
• Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy
• Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients
• A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
• Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy
• Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
• A Proof-of-Concept Study of Darbepoetin Alfa in Partial Correction of Anemia in Chinese With Diabetic Nephropathy
• Effect of Renin Angiotensin System Blockade on the Fas Antigen (CD95) and Asymmetric Dimethylarginine (ADMA) Levels in Type-2 Diabetic Patients With Proteinuria
• Aldosterone in Diabetic Nephropathy
• Shiga Progression of Diabetes, Nephropathy and Retinopathy
• Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
• Adiponectin and Insulin Resistance in Diabetic Nephropathy
• Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy
• Efficacy of Telmisartan and the Combination of Telmisartan and Ramipril in type1 Diabetes Patients With Nephropathy
• The Effect of Folic Acid Administration in the Progression of Microalbuminuria
• Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes
• Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients
• Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy
• Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy
• Bosentan Use in Patients With Diabetic Nephropathy
• Anti-Nephropathic Effects of Chronic Intermittent Intravenous Insulin Therapy (CIIIT)
• Benfotiamine in Diabetic Nephropathy
• Adiponectin in Obese Women With T2DN and Effects by RAS Blocker
• Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria
• Efficacy of N-Acetylcysteine in Treatment of Overt Diabetic Nephropathy
• Multiple Dose Trial of Anti-glycation Agent GLY-230 in Healthy and Diabetic Subjects
• Nephropathy In Type 2 Diabetes and Cardio-renal Events
• To Compare the Efficacy and Safety of Tripterygium (TW) Versus Valsartan in the Diabetic Nephropathy (DN)
• Spironolactone for Reducing Proteinuria in Diabetic Nephropathy
• Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study
• Chicken-Diet vs. Enalapril to Reduce Albuminuria
• Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy
• Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong
• Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.
• Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant
• The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
• Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus
• Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 Diabetes
• Pioglitazone and Losartan Provides Additional Renoprotection
• Controlled Study to Evaluate Efficacy and Safety of α-KA Tab With Low Protein Diet (LPD) in Delaying the Progress of Type 2 Diabetic Nephropathy (DN)
• Olmesartan Medoxomil and Diabetic Nephropathy
• Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy
• (ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy
• Renoprotection in Early Diabetic Nephropathy in Pima Indians
• Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy
• Angiotensin II Antagonism of TGF-Beta 1
• Effect of Pyridorin in Patients With Diabetic Nephropathy
• Effect of Pyridorin in Patients With Diabetic Nephropathy
• Spironolactone in Diabetic Nephropathy
• Eplerenone, ACE Inhibition and Albuminuria
• Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy
• Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy
• Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)
• Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy
• 6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria
• The Use of Cilostazol in Patients With Diabetic Nephropathy
• Study for the Effectiveness of Intensive Therapy Aiming at a Remission of Diabetic Nephropathy
• Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.
• Environmental Exposure to Lead and Progressive Renal Insufficiency in Type II Diabetic Nephropathy
• High Dose Ace Inhibitor Therapy Versus Combination of ACE and ARB Therapy
• Antialbuminuric Effects of Valsartan and Lisinopril
• Antiproteinuric Effect of Valsartan and Lisinopril
• A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril
• A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Ove
• INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy
• 1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy
• ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial
• European Trial of Immunosuppression in SPK Tx
• Nitric Oxide (NO) Activity and Diabetic Nephropathy
• Effect of Sulodexide in Overt Diabetic Nephropathy
• Effect of Sulodexide in Early Diabetic Nephropathy
• To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy
• Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease
• Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy
• Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney
• Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria
• Soy Protein in Early Diabetic Nephropathy
• Treatment of Diabetic Nephropathy
• Pirfenidone: A New Drug to Treat Kidney Disease in Patients With Diabetes
• The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
• Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes